FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
MediWound FCF Yield % Related Terms
MediWound FCF Yield % Historical Data
* Premium members only.
The historical data trend for MediWound's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:M8W vs UNCY, ARCT, NGEN: FCF Yield % Comparison
For the Biotechnology subindustry, MediWound's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediWound FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MediWound's FCF Yield % distribution charts can be found below:
* The bar in red indicates where MediWound's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediWound (FRA:M8W) has a FCF Yield % of -13.09 as of Jul. 08, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on MediWound and its competitors. According to the industry distribution chart, MediWound ranks #818 out of 1406 companies in the Biotechnology industry, placing it in the top 58.2%.
Is MediWound's FCF Yield % too high?
MediWound's current FCF Yield % is -13.09. Based on the distribution chart, MediWound ranks #818 out of 1406 companies in the Biotechnology industry, which is below the industry midpoint. Overall, MediWound has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediWound's FCF Yield % compare to UNCY and ARCT?
According to the Biotechnology industry distribution chart, MediWound ranks #818 out of 1406 companies for FCF Yield %. This places MediWound in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on MediWound and its competitors. MediWound's current FCF Yield % is -13.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediWound stock overvalued right now?
Based on GuruFocus' analysis, MediWound (FRA:M8W) is currently considered Modestly Overvalued. The stock's GF Value™ is €10.53, compared to a current price of €12.60 — trading 19.7% above its estimated fair value. The current FCF Yield % is -13.09. MediWound's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For MediWound (FRA:M8W), the current FCF Yield % is -13.09 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MediWound (FRA:M8W) Overvalued in 2026?
Based on GuruFocus' analysis, MediWound stock appears to be overvalued.
The current stock price of €12.60 is trading 19.7% above its estimated GF Value™ of €10.53.
GuruFocus considers MediWound to be Modestly Overvalued.
Key valuation signals for FRA:M8W:
FCF Yield %: -13.09
GF Value™: €10.53 vs. price of €12.60 (19.7% above fair value)
No single metric tells the full story. See the FRA:M8W stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
56GF Score
Get the complete analysis for FRA:M8W
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M8W has been successfully added to your 
